linjc16/ctgov huggingface dataset:
Comparison Between Two Optional IVC Filters Regardind Ease of Use,Complications and Outcome

Study Overview
=================
Brief Summary
-----------------
OptEase filters are easier to retrieve but the dwell time is shorter than the Gunter filters. There are more thrombi on the OptEase than on the Gunter at the time of retrieval. OptEase filter has a better infitration capabillity due to its diamond shape. OptEase filters will hjave more IVC occlusions as a complication.

Detailed Description
-----------------
We will isert the two filters blindly. We will follow the patients clinically and if needed we will add imaging exams. We will try to retrieve most filters.

Official Title
-----------------
Prospective Comparison Between OptEase and Gunter-Tulip

Conditions
-----------------
Trauma, Deep Vein Thrombosis

Intervention / Treatment
-----------------
* Device: Optease IVC filters
* Device: Gunter-Tulip IVC filters


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients referred for filter insertion Exclusion Criteria: Young age (<18 years)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Optease filter | Device: Optease IVC filters<br>* IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.<br>|
| Active Comparator: 2<br>Tulip filter | Device: Gunter-Tulip IVC filters<br>* IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparing the two filters |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVC filters, Trauma, Dwell time
Impact of Diet on Capsule Endoscopy

Study Overview
=================
Brief Summary
-----------------
Capsule endoscopy studies are used for the diagnosis of small bowel mucosal lesions. Since capsule endoscopy depends on the small intestinal peristaltism, the food intake - especially the amount of fat ingested - after the ingestion of the capsule may have an impact on the capsule endoscopy transit time and thus its diagnostic yield. As a consequence, an open-label randomized pilot study was designed to determine wether increased dietary intake of fat after the ingestion of the capsule endoscopy may influence small intestinal transit time and thus the diagnosis of small bowel lesions.

Official Title
-----------------
Impact of Diet on Capsule Endoscopy Transit Time - a Pilot Study

Conditions
-----------------
Small Bowel Disease

Intervention / Treatment
-----------------
* Procedure: Capsule endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients undergoing capsule endoscopy study Exclusion Criteria: Not being able to follow a diet with increased amount of fat

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Increased Fat Diet<br> | Procedure: Capsule endoscopy<br>* Ingestion of capsule endoscopy for the diagnosis of small bowel lesions<br>|
| Sham Comparator: Low Fat Diet<br> | Procedure: Capsule endoscopy<br>* Ingestion of capsule endoscopy for the diagnosis of small bowel lesions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Small bowel transit time |  | 12 hours |
Comparison of Two Different Treatment Methods

Study Overview
=================
Brief Summary
-----------------
A number of previous studies investigated the effects of kinesiotaping (KT) in subacromial impingement syndrome (SIS).

Detailed Description
-----------------
Subacromial impingement syndrome (SIS) is characterized by shoulder pain that is exacerbated with especially arm elevation or overhead physical activities.

Official Title
-----------------
Comparison of Short-term Effects of Two Different Treatment Methods in Patients With Subacromial Impingement Syndrome: a Randomized Controlled Single-blind Trial

Conditions
-----------------
Subacromial Impingement Syndrome, Musculoskeletal Diseases, Musculoskeletal Injury, Musculoskeletal Pain, Weakness, Muscle

Intervention / Treatment
-----------------
* Other: Kinesiotaping
* Other: Mulligan Mobilization Technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Impingement symptoms in clinical tests Pain >1 month Exclusion Criteria: Any shoulder pathology. Have chronic systemic diseases or infections. History of any surgery shoulder complex. steroid injections and therapeutic approaches

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized Controlled Trial
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control Group (CG)<br>Control group | |
| Experimental: Kinesiotaping Group (KG)<br>Experimental group | Other: Kinesiotaping<br>* KT was applied.<br>|
| Experimental: Mulligan Mobilization Technique Group (MG)<br>Experimental group (2) | Other: Mulligan Mobilization Technique<br>* MMT was applied<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of pain severity | Via VAS. | Baseline- after 2 weeks (after treatment) | 
| Change of Range of Motion | Via goniometer. | Baseline- after 2 weeks (after treatment) | 
| Change of Functionality | Via SPADI. | Baseline- after 2 weeks (after treatment) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Sleep Quality | Via VAS. | Baseline- after 2 weeks (after treatment) | 
| Change of Satisfaction of Life | Via SWLS. | Baseline- after 2 weeks (after treatment) | 
| Change of Satisfaction of Treatment | Via VAs. | Baseline- after 2 weeks (after treatment) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Subacromial Impingement Syndrome, Mulligan Mobilization Technique, Kinesiotaping, Physiotherapy
Transitional Care Interventions for Patients With Cirrhosis Post-TIPS

Study Overview
=================
Brief Summary
-----------------
The investigators conducted a randomized controlled trial to describe if multidisciplinary and patient-centered transitional care interventions for patients with cirrhosis post-TIPS can improve compliance behavior and reduce complications post-TIPS after discharge.

Official Title
-----------------
Transitional Care Interventions Post-TIPS

Conditions
-----------------
Fibrosis

Intervention / Treatment
-----------------
* Behavioral: the prevention of complications post-TIPS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of diagnosis of cirrhosis; Child-Pugh Score <10; Informed Consent. Exclusion Criteria: Age <18 years; Right ventricular failure; Severe systemic infection; Hepatocellular carcinoma (HCC); Terminal disease; and Failure to provide written consent to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>The conventional care was performed for the patients of control group | |
| Experimental: Intervention group<br>the prevention of complications post-TIPS | Behavioral: the prevention of complications post-TIPS<br>* Continuous nursing through telephone follow-up, family visits, and WeChat guided patients to prevent gastrointestinal bleeding, infection and constipation ,intake quality low-protein diet, recognize minimal encephalopathy, monitor blood ammonia, return visit regularly, deal with adverse drug reactions of anticoagulant.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The compliance behavior associated with complications post-TIPS | It was surveyed using a self-designed questionnaire based on evidence. The questionnaire includes 6 items that address taking medicine on time, quality low-protein diet intake, going to sleep at a regular time, moderate exercise, emotion regulation, regular follow-up. Item responses are on a 4-point scale (0 = never to 3 = always). Data were collected by face-to-face interviews with trained transition nurses. Change is being assessed | 1 and 3 months after discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of adverse events (shunt dysfunction and hepatic encephalopathy) | Change is being assessed | 1 and 3 months after discharge | 
| Child-Pugh scores | Change is being assessed | Baseline, 1 and 3 months after discharge | 
| Blood ammonia levels | Change is being assessed | Baseline, 1 and 3 months after discharge |
Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece

Study Overview
=================
Brief Summary
-----------------
A prospective multi-centre, non-interventional observational study, that will be conducted in several centers in Greece for a 2-year time period (completion date December 2020), to describe patient characteristics, medical history, and the clinical benefit of mepolizumab in patients with severe eosinophilic asthma newly initiated to the drug.

Conditions
-----------------
Severe Eosinophilic Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with uncontrolled severe eosinophilic asthma placed under treatment with mepolizumab, i.e. in patients with peripheral blood eosinophils ≥300 cells/μL at any measurement in the previous year or ≥150 cells/μL in a recent measurement, with poor symptom control and increased number of exacerbations (2 or more) despite optimal treatment with high doses of inhaled corticosteroids and β2 stimulants Exclusion Criteria: Patient refusal to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with uncontrolled severe eosinophilic asthma<br>Asthmatic patients with peripheral blood eosinophils ≥300 cells/μL at any measurement in the previous year or ≥150 cells/μL in a recent measurement, with poor symptom control and increased number of exacerbations (2 or more) despite optimal treatment with high doses of inhaled corticosteroids and β2 stimulants. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of annual exacerbation rate in patients with severe eosinophilic asthma in treatment with mepolizumab | Reduction of the clinical significant exacerbations in comparison to the year before the initiation of treatment with mepolizumab. A clinical significant exacerbation is an exacerbation that requires treatment as follows: increase of dose of oral corticosteroids intake | 2 years | 
| Quality of life improvement in patients with severe eosinophilic asthma receiving mepolizumab as it measured by Asthma Control Test (ACT) | ACT is a 5-point scale that assesses the frequency of shortness of breath and general asthma symptoms, use of rescue medications, the effect of asthma on daily functioning, and overall self-assessment of asthma control. An ACT score 19 or less means that asthma is not well controlled | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Severe Eosinophilic Asthma, Mepolizumab, Anti-IL5 treatment
Influence of Triathlon on the Electrolyte Balance

Study Overview
=================
Brief Summary
-----------------
Aim of the study is examining the incidence of the occurrence of hyponatremia during a Triathlon

Detailed Description
-----------------
Studies in similar endurance sports (e.g. marathon) could already indicate a high incidence for the appearance of hyponatremia during competitions. The loss of sodium through sweating and the excessive fluid intake during the competitions is a primary risk factor for the development of hyponatremia. Based on the known occurrence of hyponatremia in marathon runners, participants of the Ironman European Championship between the years 2005 and 2014 were screened for the occurrence of hyponatremia after finishing the race for safety reasons. Subjects were approached at random in the athlete's garden and invited to participate. All participants were 18 years or older.

Official Title
-----------------
Acid-base and Electrolyte Balance Among Triathletes in the Ironman European Championship

Conditions
-----------------
Hyponatremia

Intervention / Treatment
-----------------
* Behavioral: Education in nutrition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: finisher of a long-distance triathlon > 18 years < 60 years Exclusion Criteria: not finished a long-distance triathlon < 18 years > 60 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Electrolyte balance Blood sodium |  | within 20 minutes after finishing the race | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acid balance |  | within 20 minutes after finishing the race | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ironman, Triathlon
To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg

Study Overview
=================
Brief Summary
-----------------
To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg.

Official Title
-----------------
Bioavailability of Alprazolam Tablets, 2 mg.

Conditions
-----------------
Anxiety

Intervention / Treatment
-----------------
* Drug: Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B or C. Treatment for drug or alcohol dependence.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.) | Drug: Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)<br> <br> |
| Active Comparator: 2<br>Alprazolam Tablets, 2 mg, Xanax (The Upjohn Company) | Drug: Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence based on AUC and Cmax |  | 13 days |
The Follow up of Chinese Young Children With Melamine-Related-Calculus

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the lesions, clinical features and outcome in young children with melamine-related-calculus.

Detailed Description
-----------------
To investigate the outcome of melamine-related-calculus. The change of calculus. The change of obstruction features,including hydronephrosis and ureterectasia. The change of the urinalysis. To investigate the change of renal function in children with melamine-related-calculus during the follow up. Creatinine, urea and uric acid. α and β2 microglobulin. To analysis the factors might be associated with the outcome. The characteristics of patients: age, gender, and so on. The characteristics of calculus: location, size, and so on.

Official Title
-----------------
Part 1 The Outcome of Children With Melamine-Related-Calculus

Conditions
-----------------
Calculus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children with melamine-related-calculus: with a history of melamine contaminated products the parents leave the detailed information for contact and willing to be recalled Exclusion Criteria: children with other congenital renal abnormality children with hypercalciuria children have abnormality of parathyroid gland

Ages Eligible for Study
-----------------
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The calculus measured by sonography |  | at 1, 3, 6 and 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal function (e.g., creatinine, microglobulin) |  | at 1, 3, 6 and 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Melamine, Calculus, Kidney, Child
Prevalence of Rest Dyspnea and Impact of Non Invasive Ventilation on Breathing Sensations in CCHS Patients

Study Overview
=================
Brief Summary
-----------------
Congenital central hypoventilation syndrome (CCHS) is a neuro-respiratory disease characterized by lifethreatening sleep-related hypoventilation involving an alteration of CO2/H+ chemosensitivity. This suggests cortical activity during awakening to maintain breathing. Cortical activity to keep breathing is usually associated with breathing discomfort ; this is the case in healthy subjects under non invasive ventilation (NIV) or with expiratory charge as well as in patients with amyotrophic lateral sclerosis. This can suggest that CCHS may be breathless at rest and this discomfort could be reduced by NIV. The objective is to evaluate dyspnea with a multi dimensional score, MDP, in CCHS patient at rest in every day life and during 1H session of NIV. The investigators will perform a prospective, including 20 CCHS patients. MDP scores will be measure before and after 1H-non invasive ventilation as well as a visual scale of 100mm in order to evaluate variation of breathing discomfort before/after NIV. The investigators expect that CCHS patients don't have rest dyspnea but NIV would improve breathing discomfort that would mean they have latent rest dyspnea.

Official Title
-----------------
Prevalence of Rest Dyspnea and Impact of Non Invasive Ventilation on Breathing Sensations in Patients With Congenital Central Hypoventilation Syndrome

Conditions
-----------------
CCHS, Congenital Central Hypoventilation Syndrome, Dyspnea

Intervention / Treatment
-----------------
* Other: MDP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with CCHS confirmed by genetic test patients with long term non invasive ventilation no recent condition that could impact breathing sensations such as infection, pulmonary embolism, heart failure Exclusion Criteria: pregnancy phrenic nerve stimulation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CCHS<br>20 patients presenting with central hypoventilation syndrome during spontaneous breathing and with Non Invasive Ventilation | Other: MDP<br>* Multi dimensional dyspnea profile scores at rest and during non invasive ventilation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immediate unpleasantness corresponding to A.1 item of the multidimensional dyspnea profile | Measure MDP scores before and after NIV | Change in MDP score between baseline and after 1 hour of NIV |